Precision Biosensor

Precision Biosensor Financing Cash Flow

The Net Financing Cash Flow of Precision Biosensor (335810.KQ) as of Nov 2, 2026 is -5.01 B KRW. In the previous year, Net Financing Cash Flow was 6.72 B KRW — a change of -174.57% (lower).

Financing Cash Flow

-5.01 BKRW

YoY

-174.57%

Last updated:

Net Financing Cash Flow of Precision Biosensor is 2024 -5.01 B KRW. Net Financing Cash Flow of Precision Biosensor was 2023 6.72 B KRW. It decreases by -174.57% lower compared to the previous year.

The Precision Biosensor Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
7.94 B KRW
Jan 1, 2018
-310,510.00 KRW
Jan 1, 2019
10.73 B KRW
Jan 1, 2020
20.05 B KRW
Jan 1, 2021
17.45 B KRW
Jan 1, 2022
4.21 B KRW
Jan 1, 2023
6.72 B KRW
Jan 1, 2024
-5.01 B KRW
The Precision Biosensor Financing Cash Flow history
YEARFinancing Cash FlowYoY
-5.01 BKRW-174.57%
6.72 BKRW+59.68%
4.21 BKRW-75.87%
17.45 BKRW-13.01%
20.05 BKRW+86.84%
10.73 BKRW-3.46 M%
-310,510.00KRW-100.00%
7.94 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Net Financing Cash Flow of Precision Biosensor is -5.01 B KRW in 2024.

Net Financing Cash Flow of Precision Biosensor changed from 6.72 B KRW to -5.01 B KRW, representing a -174.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Precision Biosensor historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Precision Biosensor

All Key Metrics — Precision Biosensor